title: [Chemotherapy for prostate cancer].
abstract: Chemotherapy treatment for patients with prostate cancer has advanced considerably during the past decade. The first demonstration of the efficacy of palliative chemotherapy in patients with hormone-resistant prostate cancer was followed by FDA approval of mitoxantrone in this setting and by studies showing the usefulness of several different drugs in these patients. Docetaxel became the standard treatment for them. The development of new cytotoxic molecules and targeted therapies as well as the evaluation of the efficacy of docetaxel in earlier stages of prostate cancer, with many ongoing studies, are the current lines of research for improving management of these hormone-refractory patients.
authors.affiliation: Département de cancérologie médicale, Hôpital européen Georges Pompidou, F-75015 Paris, France. jacques.medioni@egp.aphp.fr <jacques.medioni@egp.aphp.fr>
authors.forename: Jacques
authors.initials: J
authors.lastname: Medioni
authors.forename: Dimitri
authors.initials: D
authors.lastname: Dionysopoulos
authors.forename: Eugéniu
authors.initials: E
authors.lastname: Banu
authors.forename: Floriant
authors.initials: F
authors.lastname: Scotté
authors.forename: Philippe
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D014815:Vitamins; D000077143:Docetaxel; D004961:Estramustine; D002117:Calcitriol